A phase II−III trial of olesoxime in subjects with amyotrophic lateral sclerosis

To assess the efficacy and safety of olesoxime, a molecule with neuroprotective properties, in patients with amyotrophic lateral sclerosis (ALS) treated with riluzole.

[1]  O. Hardiman,et al.  Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial , 2013, The Lancet Neurology.

[2]  L. Rubin,et al.  A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. , 2013, Cell stem cell.

[3]  B. Pettmann,et al.  Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model , 2012, Neuropharmacology.

[4]  G. Bennett,et al.  Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel , 2012, Neuroscience.

[5]  V. Meininger,et al.  Improving survival in a large French ALS center cohort , 2012, Journal of Neurology.

[6]  V. Gribkoff,et al.  The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis , 2011, Nature Medicine.

[7]  V. Meininger,et al.  How can we improve clinical trials in amyotrophic lateral sclerosis? , 2011, Nature Reviews Neurology.

[8]  P. Shaw,et al.  Review: The role of mitochondria in the pathogenesis of amyotrophic lateral sclerosis , 2011, Neuropathology and applied neurobiology.

[9]  M. Cudkowicz,et al.  Emerging targets and treatments in amyotrophic lateral sclerosis , 2011, The Lancet Neurology.

[10]  M. Carré,et al.  Olesoxime prevents microtubule-targeting drug neurotoxicity: selective preservation of EB comets in differentiated neuronal cells. , 2010, Biochemical pharmacology.

[11]  G. Bennett,et al.  Olesoxime (cholest-4-en-3-one, oxime): Analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel , 2009, PAIN®.

[12]  D. Schoenfeld,et al.  The natural history of ALS is changing: Improved survival , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[13]  Merit Cudkowicz,et al.  ALS drug development: Reflections from the past and a way forward , 2008, Neurotherapeutics.

[14]  B. Buisson,et al.  Specific Antinociceptive Activity of Cholest-4-en-3-one, Oxime (TRO19622) in Experimental Models of Painful Diabetic and Chemotherapy-Induced Neuropathy , 2008, Journal of Pharmacology and Experimental Therapeutics.

[15]  J. E. Kranz,et al.  Design, power, and interpretation of studies in the standard murine model of ALS , 2008, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[16]  H. Mitsumoto,et al.  Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial , 2007, The Lancet Neurology.

[17]  C. Henderson,et al.  Identification and Characterization of Cholest-4-en-3-one, Oxime (TRO19622), a Novel Drug Candidate for Amyotrophic Lateral Sclerosis , 2007, Journal of Pharmacology and Experimental Therapeutics.

[18]  P. Kaufmann,et al.  Pentoxifylline in ALS , 2006, Neurology.

[19]  P. Shaw,et al.  Apoptosis in amyotrophic lateral sclerosis—what is the evidence? , 2005, The Lancet Neurology.

[20]  T. Conrad,et al.  A clinical trial of creatine in ALS , 2004, Neurology.

[21]  V. Meininger,et al.  Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials , 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[22]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[23]  J. Cedarbaum,et al.  The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function , 1999, Journal of the Neurological Sciences.

[24]  P. Leigh,et al.  Dose-ranging study of riluzole in amyotrophic lateral sclerosis , 1996, The Lancet.

[25]  M. Swash,et al.  Preclinical and subclinical events in motor neuron disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[26]  P. Leigh,et al.  What do people at risk for Alzheimer disease think about surrogate consent for research? , 2005, Neurology.

[27]  P. Leigh,et al.  Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. , 1996, Lancet.